Tennis Pro Caroline Wozniacki’s Advantage Hers Campaign Supports Women with Inflammatory Conditions

Caroline Wozniacki has led an interesting life. Born in Denmark, she was immediately thrust into athleticism. Her father was a former football player (that's soccer for you Americans) and her…

Continue Reading Tennis Pro Caroline Wozniacki’s Advantage Hers Campaign Supports Women with Inflammatory Conditions
Ankylosing Spondylitis Treatment Approved but Not Yet Available
https://pixabay.com/en/approved-pass-ok-approval-symbol-1726357/

Ankylosing Spondylitis Treatment Approved but Not Yet Available

According to Ankylosing Spondylitis News, a new treatment, Hulio, has been approved by the FDA. It is a treatment for ankylosing spondylitis and other inflammatory disorders. Although it has been…

Continue Reading Ankylosing Spondylitis Treatment Approved but Not Yet Available
Simponi Works for Patients with AS, RA, and PsA – Even with Prior TNF Inhibitor Treatment
mohamed_hassan / Pixabay

Simponi Works for Patients with AS, RA, and PsA – Even with Prior TNF Inhibitor Treatment

  In some cases, people have a medical condition that doesn't respond well to treatments. The journey to finding an effective treatment can be long and difficult. But for patients…

Continue Reading Simponi Works for Patients with AS, RA, and PsA – Even with Prior TNF Inhibitor Treatment

A Subcutaneous Form of Remsima May be Available Soon in the EU

Celltrion Healthcare has just announced positive progress for extending the authorization for the subcutaneous (SC) form of Remsima to five more autoimmune conditions. These are- Psoriatic arthritis Ankylosing spondylitis (AS)…

Continue Reading A Subcutaneous Form of Remsima May be Available Soon in the EU
Psoriasis Drug Now a Potential Candidate to Treat PsA and Uveitis
Hans / Pixabay

Psoriasis Drug Now a Potential Candidate to Treat PsA and Uveitis

  According to LabioTech, a psoriasis drug developed by biotechnology company Affibody showed promising results in a Phase II clinical trial (AFFIRM-35). This trial, which consisted of 108 participants with…

Continue Reading Psoriasis Drug Now a Potential Candidate to Treat PsA and Uveitis

New Lifestyle Guidelines Will Improve QOL for Patients with Rheumatic and Musculoskeletal Diseases (RMDs)

At this year's EULAR 2020 E-Congress, Dr. Suzanne Verstappen, MD, presented on how lifestyle changes could benefit patients with rheumatic and musculoskeletal diseases (RMDs). Her interest in the impact of…

Continue Reading New Lifestyle Guidelines Will Improve QOL for Patients with Rheumatic and Musculoskeletal Diseases (RMDs)
Novartis Cosentyx® Receives Positive CHMP Opinion for Non-Radiographic Axial Spondyloarthritis Treatment
source: pixabay.com

Novartis Cosentyx® Receives Positive CHMP Opinion for Non-Radiographic Axial Spondyloarthritis Treatment

  According to a press release on Global Newswire, Novartis has received a positive opinion on Cosentyx® from the Committee for Medicinal Products for Human Use (CHMP). This positive opinion…

Continue Reading Novartis Cosentyx® Receives Positive CHMP Opinion for Non-Radiographic Axial Spondyloarthritis Treatment
A Simple Blood Test Could Lead to Personalized Therapies for Rheumatoid Arthritis and Related Diseases
source: pixabay.com

A Simple Blood Test Could Lead to Personalized Therapies for Rheumatoid Arthritis and Related Diseases

A recent study led by Morten Aagaard Nielsen and Tue Wenzel Kragstrup, who both work at Aarhus University in Denmark, hopes to help physicians determine the best personalized treatment for…

Continue Reading A Simple Blood Test Could Lead to Personalized Therapies for Rheumatoid Arthritis and Related Diseases
IL-23 Inhibitors May be a Leading Treatment for Psoriasis and Psoriatic Arthritis
source: pixabay.com

IL-23 Inhibitors May be a Leading Treatment for Psoriasis and Psoriatic Arthritis

The 2019 European Academy of Dermatology and Venereology Congress was held in Madrid, Spain. During this conference, a symposium was held discussing IL-23 inhibition in psoriasis. Here are some of…

Continue Reading IL-23 Inhibitors May be a Leading Treatment for Psoriasis and Psoriatic Arthritis
The FDA Grants Breakthrough Therapy Designation for ORENCIA as a Treatment for Graft vs Host Disease
source: pixabay.com

The FDA Grants Breakthrough Therapy Designation for ORENCIA as a Treatment for Graft vs Host Disease

According to a story from Business Wire, the biopharmaceutical company Bristol-Myers Squibb has recently announced that the US Food and Drug Administration (FDA) has granted the company's drug abatacept (marketed…

Continue Reading The FDA Grants Breakthrough Therapy Designation for ORENCIA as a Treatment for Graft vs Host Disease
Results of Phase 3 Trial Suggest The Drug Cosentyx Could be Effective for Axial Spondyloarthritis
source: pixabay.com

Results of Phase 3 Trial Suggest The Drug Cosentyx Could be Effective for Axial Spondyloarthritis

According to a story from Ankylosing Spondylitis News, findings from a phase 3 clinical trial suggest that the drug secukinumab (marketed as Cosentyx) could be an effective treatment for non-radiographic…

Continue Reading Results of Phase 3 Trial Suggest The Drug Cosentyx Could be Effective for Axial Spondyloarthritis
A Drug Used to Treat Psoriasis Could be Effective for Ulcerative Colitis
Pexels / Pixabay

A Drug Used to Treat Psoriasis Could be Effective for Ulcerative Colitis

According to a story from Medical News Bulletin, a recent study that was first published in the New England Journal of Medicine appears to have revealed a promising new treatment for ulcerative…

Continue Reading A Drug Used to Treat Psoriasis Could be Effective for Ulcerative Colitis
Combined Clinics Improves Treatment for Autoimmune Diseases
Movidagrafica / Pixabay

Combined Clinics Improves Treatment for Autoimmune Diseases

According to a story from The Rheumatologist, evidence suggests that patients with rare diseases, such as autoimmune diseases, can benefit from visiting combined clinics, which are special medical centers in…

Continue Reading Combined Clinics Improves Treatment for Autoimmune Diseases
A “Real World” Study Suggests That The Drug Apremilast Could be Useful for Behçet’s Disease
katicaj / Pixabay

A “Real World” Study Suggests That The Drug Apremilast Could be Useful for Behçet’s Disease

According to a story from rheumatology.medicinematters.com, a recent Italian real-world study has provided some evidence that the drug apremilast, which is considered a phosphodiesterase-4 inhibitor, could be a useful treatment…

Continue Reading A “Real World” Study Suggests That The Drug Apremilast Could be Useful for Behçet’s Disease
Biosimilar Drug for Ankylosing Spondylitis gets Approved by the FDA
stevepb / Pixabay

Biosimilar Drug for Ankylosing Spondylitis gets Approved by the FDA

According to a story from Ankylosing Spondylitis News, the drug Hadlima, which is a biosimilar to the drug Humira (adalimumab), was recently approved by the US Food and Drug Administration…

Continue Reading Biosimilar Drug for Ankylosing Spondylitis gets Approved by the FDA
Researchers Continue Search for Role of Type-1 Interferon Pathway in Rheumatic Disease
mohamed_hassan / Pixabay

Researchers Continue Search for Role of Type-1 Interferon Pathway in Rheumatic Disease

According to a publication from the Rheumatologist, past studies have suggested that type 1 interferons may play a significant role in determining susceptibility to several classic connective tissue diseases. Although…

Continue Reading Researchers Continue Search for Role of Type-1 Interferon Pathway in Rheumatic Disease

Otezla Receives FDA Approval for Treatment of Oral Sores that Characterize Behçet’s Disease

According to a press release from American biotechnology company Celgene Corporation, the American Food and Drug Administration (FDA) recently approved the Company's drug Otezla (generic name apremilast) for the treatment…

Continue Reading Otezla Receives FDA Approval for Treatment of Oral Sores that Characterize Behçet’s Disease

New Biosimilar Product to Humira Could Be Cheaper and Just as Effective for Ankylosing Spondylitis Patients

The most common treatment for autoimmune conditions such as ankylosing spondylitis, plaque psoriasis, Crohn's disease, juvenile idiopathic arthritis, and rheumatoid arthritis is currently a drug called Humira, created by AbbVie.…

Continue Reading New Biosimilar Product to Humira Could Be Cheaper and Just as Effective for Ankylosing Spondylitis Patients
Close Menu